ZF874 / Centessa - LARVOL DELTA

A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiXZ Subjects (clinicaltrials.gov) - P1 | N=69 | Terminated | Sponsor: Z Factor Limited | Active, not recruiting ➔ Terminated; Based on the results observed to date, the Sponsor concluded that ZF874 was unlikely to achieve the desired target product profile.

Trial termination • Alpha-1 Antitrypsin Deficiency • Hepatology • Respiratory Diseases

A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiXZ Subjects (clinicaltrials.gov) - P1 | N=69 | Active, not recruiting | Sponsor: Z Factor Limited | Recruiting ➔ Active, not recruiting

Enrollment closed • Alpha-1 Antitrypsin Deficiency • Hepatology • Respiratory Diseases

A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiXZ Subjects (clinicaltrials.gov) - P1; N=73; Recruiting; Sponsor: Z Factor Limited; Trial completion date: Jan 2022 ➔ Sep 2022; Trial primary completion date: Jan 2022 ➔ Sep 2022

Clinical • Trial completion date • Trial primary completion date • Alpha-1 Antitrypsin Deficiency • Hepatology • Respiratory Diseases

A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiXZ Subjects (clinicaltrials.gov) - P1; N=68; Recruiting; Sponsor: Z Factor Limited; Trial completion date: Oct 2021 ➔ Jan 2022; Trial primary completion date: Oct 2021 ➔ Jan 2022

Clinical • Trial completion date • Trial primary completion date • Alpha-1 Antitrypsin Deficiency • Hepatology • Respiratory Diseases

A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiXZ Subjects (clinicaltrials.gov) - P1; N=68; Recruiting; Sponsor: Z Factor Limited; Trial completion date: Jul 2021 ➔ Oct 2021; Trial primary completion date: Jul 2021 ➔ Oct 2021

Clinical • Trial completion date • Trial primary completion date • Alpha-1 Antitrypsin Deficiency • Hepatology • Respiratory Diseases

A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiXZ Subjects (clinicaltrials.gov) - P1; N=62; Recruiting; Sponsor: Z Factor Limited; N=40 ➔ 62

Clinical • Enrollment change • Alpha-1 Antitrypsin Deficiency • Hepatology • Respiratory Diseases

First subject dosed with ZF874, a potential disease-modifying treatment for alpha-1-antitrypsin deficiency (Cambridge Network) - "Z Factor Ltd...announced that the first human volunteer was dosed today with ZF874, its novel treatment for alpha-1-antitrypsin deficiency (AATD)....'This trial is designed to allow us to determine how safe and effective it is at raising Z-A1AT levels in humans in a short period of time. We expect to have top-line results for this potentially disease-modifying treatment in subjects carrying the Z mutation by the end of this year'....Cambridge Enterprise, the commercialisation arm of the University of Cambridge, licensed the technology into Z Factor. Cambridge Enterprise also participated in both the seed round and the Series A round....The funding allowed the team to leverage this window onto the folding defect caused by the Z mutation, working in collaboration with the local out-sourced discovery platform company, RxCelerate, to create ZF874."

Financing • P1 data • Trial status • Alpha-1 Antitrypsin Deficiency

A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiMZ Subjects (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Z Factor Limited; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Alpha-1 Antitrypsin Deficiency

A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiMZ Subjects (clinicaltrials.gov) - P1; N=40; Not yet recruiting; Sponsor: Z Factor Limited

Clinical • New P1 trial • Alpha-1 Antitrypsin Deficiency